Status:
COMPLETED
Long Term Safety of Aliskiren Alone or With the Optional Addition of Hydrochlorothiazide in Patients With Essential Hypertension
Lead Sponsor:
Novartis
Conditions:
Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Assess the long-term safety and tolerability of aliskiren, with the optional addition of HCTZ, in patients with essential hypertension, to ensure long term blood pressure control and protect against e...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Patients with essential hypertension.
- Patients who are eligible and able to participate in the study.
- Exclusion Criteria
- Severe hypertension.
- History or evidence of a secondary form of hypertension.
- History of hypertensive encephalopathy or cerebrovascular accident. Other protocol-defined exclusion criteria may apply.
Exclusion
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2005
Estimated Enrollment :
1955 Patients enrolled
Trial Details
Trial ID
NCT00219037
Start Date
June 1 2004
End Date
October 1 2005
Last Update
November 8 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigative Sites, Germany